PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no nervous required to respond to a collection of information unless it contains a until OMFR

				Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/003,462	
			LOSURE	Filing Date	12/06/2001	
				First Named Inventor	Sierra et al.	
			cessary)	Art Unit	1643	
				Examiner Name	Anne L. Holleran	
Sheet	1	Of	1	Attorney Docket Number	30797-717.201	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Aun	1.	US-5,894,018	04-13-1999	Gandolf et al.		
V	2.	US-5,690,928	11-25-1997	Heimbrook et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials®	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohimms, Lines, Where Relevant Passages or Relevant Figures Appear	Te
. All	3.	GB-2,333,706 A	08-04-1999	Merck & Co. Inc.		
ALH	4.	WO-1991-01146 A	02-07-1991	Praxis Biolog Inc.	- "	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T⁵			
ALH	5.	D'ERRICO et al., "Role and new perspectives of transforming growth factor-alpha (TGF-a1) adenocarcinoma of the gastro-oesophageal junction," Br. J. Cancer, Vol. 82(4), Feb. 2000, pp. 865-870				

		Uallaman/	/11/07/2006\	
Examiner	/ All	ne norreran/	(11/07/2206)	
Signature			Considered.	

Signature | Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 'For Ispanese patent documents, the indication of the year of the reign of the feign or unst precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is stateched.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the smount of time you require to complete this form under suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.